Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 1/20 | 0.37 |
| ▸ | CTSL | P07711 | 1/20 | 0.30 |
| ▸ | CTSB | P07858 | 1/20 | 0.30 |
| ▸ | CTSS | P25774 | 1/20 | 0.30 |
| ▸ | CTSK | P43235 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL288906 | 1.00 | FAAH (0.37) | FAAHCTSLCTSBCTSSCTSK | |
| SCHEMBL15663456 | 1.00 | FAAH (0.37) | FAAHCTSLCTSBCTSSCTSK | |
| Ammonia Solution, Strong SCHEMBL15303247 | 0.98 | FAAH (0.36) | FAAH | |
| SCHEMBL12629160 | 0.83 | FAAH (0.37) | FAAHCTSLCTSBCTSSCTSK | |
| SCHEMBL10980085 | 0.83 | FAAH (0.37) | FAAHCTSLCTSBCTSSCTSK | |
| SCHEMBL16234969 | 0.80 | FAAH (0.35) | FAAH | |
| SCHEMBL4480182 | 0.80 | FAAH (0.35) | FAAHCTSLCTSBCTSSCTSK | |
| SCHEMBL19746826 | 0.80 | FAAH (0.35) | FAAHCTSLCTSBCTSSCTSK | |
| SCHEMBL22030293 | 0.80 | CTSL (0.37) | FAAHCTSLCTSBCTSSCTSK | |
| SCHEMBL10988574 | 0.80 | CTSL (0.37) | FAAHCTSLCTSBCTSSCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 59 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117529476-A | Preparation of substituted 1, 2-diamino heterocyclic derivatives and their use as medicaments | 亚飞络思制药公司 | 2024-02-06 | — | — | CN | disclosed |
| EP-3402777-B1 | OXAZOLIDINONES AS TARO INHIBITORS | MERCK SHARP & DOHME (US) | 2023-12-13 | — | — | EP | disclosed |
| US-11738010-B2 | Oxazolidinones as TarO inhibitors | MERCK SHARP & DOHME CORP. (US) | 2023-08-29 | — | — | US | disclosed |
| US-20230138851-A1 | NOVEL ALKYNE DERIVATIVES | CARNA BIOSCIENCES, INC. (JP) | 2023-05-04 | — | — | US | disclosed |
| US-11623927-B2 | Substituted [1,2,4]triazolo[1,5-a]pyrimidines for stabilizing microtubules | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2023-04-11 | — | — | US | disclosed |
| WO-2023051495-A1 | ISOQUINOLINONE AND QUINAZOLINONE COMPOUNDS, AND COMPOSITION AND USE THEREOF | 中山医诺维申新药研发有限公司 | 2023-04-06 | — | — | WO | disclosed |
| CN-113616656-B | Heterocyclic compounds for the treatment of PI 3K-gamma mediated disorders | 无限药品股份有限公司 | 2023-02-17 | — | — | CN | disclosed |
| CN-109476668-B | 6, 7-dihydro-4H-pyrazolo [1,5-a ] pyrazines and 6, 7-dihydro-4H-triazolo [1,5-a ] pyrazines for the treatment of infectious diseases | 豪夫迈·罗氏有限公司 | 2022-03-22 | — | — | CN | disclosed |
| EP-3448839-B1 | QUINAZOLINE DERIVATIVE OR ITS SALT AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME | YUHAN CORP (KR) | 2022-02-09 | — | — | EP | disclosed |
| US-20210346364-A1 | OXAZOLIDINONES AS TARO INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2021-11-11 | — | — | US | disclosed |
| US-6949577-B2 | Pharmaceuticals | PFIZER, INC. (US) | 2005-09-27 | — | — | US | disclosed |
| EP-1264826-B1 | NOVEL IMIDAZOLINE COMPOUNDS | BANYU PHARMA CO LTD (JP) | 2005-03-30 | — | — | EP | disclosed |
| US-6869966-B2 | N-substituted-2-oxodihydropyridine derivatives | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2005-03-22 | — | — | US | disclosed |
| US-20050043368-A1 | Propylcarbamate derivatives as inhibitors of serine and cysteine proteases | SMITHKLINE BEECHAM CORPORATION | 2005-02-24 | — | — | US | disclosed |
| US-20050009879-A1 | Chemical intermediates for their production such as 1-ethyl-2-pyridone-5-carboxylic acid; neuropeptide Y receptor antagonists; for treatment of cardiovascular disorders, glaucoma, and eating disorders | MSD K.K. (JP) | 2005-01-13 | — | — | US | disclosed |
| US-20040072874-A1 | N-substituted-2-oxodihydropyridine derivatives | MSD K.K. (JP) | 2004-04-15 | — | — | US | disclosed |
| US-20030236420-A1 | Pharmaceuticals | ALLERTON CHARLOTTE MOIRA NORFO (GB) | 2003-12-25 | — | — | US | disclosed |
| US-20030158418-A1 | Novel imidazonline compounds | MSD K.K. (JP) | 2003-08-21 | — | — | US | disclosed |
| EP-1264826-A1 | NOVEL IMIDAZOLINE COMPOUNDS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-12-11 | — | — | EP | disclosed |
| US-20020147229-A1 | Pharmaceuticals | PFIZER INC. | 2002-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043368-A1 | Propylcarbamate derivatives as inhibitors of serine and cysteine proteases | CTSK, CTSB, CTSS | FAAH 903/4885CTSL 22/4885CTSB 2/4885 |
| US-11623927-B2 | Substituted [1,2,4]triazolo[1,5-a]pyrimidines for stabilizing microtubules | TUBB1, TUBA1B, TUBA1C | FAAH 4221/4885CTSL 4683/4885CTSB 4096/4885 |
| US-20210346364-A1 | OXAZOLIDINONES AS TARO INHIBITORS | OXA1L, DDO, ALPI | FAAH 4546/4885CTSL 1442/4885CTSB 1253/4885 |
| US-20230138851-A1 | NOVEL ALKYNE DERIVATIVES | DYRK1B, DYRK3, DYRK2 | FAAH 3416/4885CTSL 3146/4885CTSB 2111/4885 |
| US-20050009879-A1 | Chemical intermediates for their production such as 1-ethyl-2-pyridone-5-carboxylic acid; neuropeptide Y receptor antagonists; for treatment of cardiovascular disorders, glaucoma, and eating disorders | NPY1R, NPY2R, NPY4R | FAAH 113/4885CTSL 1301/4885CTSB 1293/4885 |
| US-20020147229-A1 | Pharmaceuticals | BDKRB1, TFPI, BDKRB2 | FAAH 275/4885CTSL 1107/4885CTSB 497/4885 |
| US-20030158418-A1 | Novel imidazonline compounds | NPY1R, NPY2R, GPR119 | FAAH 584/4885CTSL 1648/4885CTSB 2719/4885 |
| US-20030236420-A1 | Pharmaceuticals | BDKRB1, TFPI, SERPINE1 | FAAH 356/4885CTSL 1007/4885CTSB 393/4885 |
| US-11738010-B2 | Oxazolidinones as TarO inhibitors | OXA1L, DDO, ALPI | FAAH 4546/4885CTSL 1442/4885CTSB 1253/4885 |
| US-20040072874-A1 | N-substituted-2-oxodihydropyridine derivatives | GPR119, NPY4R, NPY1R | FAAH 228/4885CTSL 1980/4885CTSB 1423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.